Condition
Liver Fibrosis Due to NASH
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
2 of 0 completed with results
Key Signals
2 with results0
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Terminated2
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06797596Not Yet RecruitingPrimary
Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.
NCT01672866Phase 2TerminatedPrimary
Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
NCT01672879Phase 2TerminatedPrimary
Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH
Showing all 3 trials